Ongoing research has elucidated a large variety of genes, proteins and enzyme products that are affected in epilepsy. Despite the pharmacological advances achieved by the development of antiepileptic drugs, numerous patients become pharmacoresistant.
Epilepsy affects about 1% of the human population at some point during their life. The causes of human epilepsies are diverse, ranging from defects during brain development resulting in dysplasias or ectopic cortical neurons to inherited forms involving certain mutations, e.g. ion channel defects or metabolic impairments; however, most causes are still unknown. 1, 2 Furthermore, posttraumatic epilepsies are also known; 3 therefore, epilepsies are not a homogeneous pathogenetical entity, but rather are defined as the "occurrence of repeated seizures", 4 which will be grouped into various epileptic syndromes according to the individual semiology of patients. 5 The causes of the initial mechanisms in the development of epileptic seizures are still elusive and only partial aspects of specific epileptic phenomena may be attributable to mutations at certain gene loci. [6] [7] [8] Furthermore, during onset and progression of the disease, multiple changes in the expression patterns of many genes and gene products have been reported. 2, 9 This indicates that there are no single and specific gene mutations associated with a certain type of epilepsy, as has been established for Huntington's disease, for example. These multiple molecular responses (at the level of genes, RNA splicing and proteins) provide strong evidence for the induction of pathology-associated responses.
In our view, these changes are best explained as an initiation of compensatory gene-expression cascades (CGECs), i.e. a response to cope with the primary functional alterations caused by the disease (e.g. changes in the expression of neurotransmitter receptors or stress-response genes). These primary CGECs (pCGECs) are followed by additional secondary endogenous responses (e.g. an upregulation of multidrug transporters at the blood-brain barrier or certain neurons 10 ) and tertiary responses induced by the short-and long-term effects of specific pharmacological interventions. This tertiary response may also be described as an exogenously or pharmacologically induced phCGEC.
According to these multifactorial and interdependent mechanisms, in vivo animal models continue to play a major role in the elucidation and understanding of the ongoing pathomechanisms, as well as the response mechanisms to pharmacological intervention and therapy. Most authors argue that models in which neurodegeneration occurs are justified as they resemble the situation observed in patients with epilepsy. [18] [19] [20] However, successful therapeutic intervention in epilepsy may depend on the understanding and rapid treatment of early symptoms, which may precede the situation observed in cerebral tissue dissected from patients with a long history of seizure semiology. Therefore, the PTZ models may offer the opportunity to address this latter aspect, as the PTZ model of 'repeated series of seizures' using PTZ 40mg/kg bodyweight produces a pattern of seizures that matches that observed in patients (see Figure 1 ). As it is beyond the scope of this article to address all aspects of PTZinduced seizures as previously described and discussed, 4 we would like to focus on effects reported for neurotransmitter receptors and associated stress responses.
Pentylenetetrazole-induced Seizures and Neurotransmission
For PTZ-kindled mice and during acutely PTZ-induced tonic-clonic seizures in mice, clear time-dependent changes in the amount of adenosine (A1) receptors are known, which also depend on the duration of the kindling process. [22] [23] [24] [25] [26] In general, A1-binding sites were increased in cortical, hippocampal and cerebellar regions, whereas 27 following PTZ-induced seizure episodes, whereas no significant changes were reported for the rat 24 hours after the last tonic-clonic seizures. 26 However, focusing on the N-methyl-Daspartic acid (NMDA) receptor in mice, a long-lasting upregulation of NMDA-binding sites occurs in mice, which has also been seen in rats. 26, 28 Kainate receptors have long been associated with epilepsy, but despite the obvious use of the so-called kainate model, their direct relation to epileptic seizures is still a matter for discussion due to their ubiquitous distribution and multiple functions. In fully PTZkindled rats and in the PTZ model of a repeated series of seizures, kainate-binding sites are significantly reduced (see Figure 2) . 26, 30 Therefore, the overall differences reported for the glutamate receptors among mice and rats could be related to the post-seizure times at which the measurements were performed. Despite these model-specific differences, it should be emphasised that a combined inhibition of AMPA and NMDA receptors prevents PTZinduced tonic-clonic seizures. 29 In contrast to the more ubiquitous downregulation of kainate receptors, dopamine receptors (D1 and D2) become reduced in a more region-specific manner, mostly affecting the amygdala. 31 Effects have also been described or postulated for the other monoaminergic receptors, mainly as compensatory responses to PTZ kindling. 32, 33 Despite the fact that PTZ has been shown to be an antagonist at 
Oxidative and Nitrosative Stress
For various PTZ models, oxygen-and pH-related changes were reported early in the history of seizure semiology. 34 As in most other models of experimental epilepsy, clear signs of oxidative stress occur shortly after PTZ application, such as alterations of the thiol redox state and lipid and protein oxidation. [35] [36] [37] After PTZ-induced seizures and kindling, the formation of the reactive hydroxyl radical and an increase in NO metabolites has been reported, 38 
The Topography of Stress Responses
As explained above, it is now well-established that seizure-related hyperactivity is associated with oxidative stress. From a neurophysiological point of view, certainly one of the most convincing aspects for an association of neuronal excitation and oxidative responses is related to the arachidonic acid pathway and prostaglandin synthesis via cyclo-oxygenases (COX-1, COX-2); in particular, the inducible form COX-2 is constitutively expressed in a region-specific manner in many cerebral neurons in which COX-2 expression and activity is regulated by synaptic activity. In addition, it should be noted that under normal physiological conditions cerebral regions well-known for their high constitutive COX-2 expression are those that belong to the epileptic circuitry. attenuate seizure activity. 43, 44 Although not as strong as in rat models for cerebral ischaemia, 45, 46 COX-2 expression is induced in human patients with epilepsy 47 and in the model of repeated PTZinduced seizures (see Figure 3) . COX-2-expressing neurons are shown to be closely associated with the processes of neurons expressing nNOS, thus revealing a direct topographical link between COX-2-related superoxide and NOS-I-related NO production. As the normal constitutive neuronal expression of COX-2 and the seizure-induced induction of COX-2 take place in a region-specific manner, COX-2-related production of oxygen radicals may represent the basis for region-specific pathological changes attributed to seizure-induced oxidative stress.
Some of the most affected cortical regions are the piriform and entorhinal cortices, which exhibit not only high COX-2 expression (see Figure 3 ), but also one of the highest packing densities of NOS-I-expressing cortical neurons. 48, 49 This association of neurons responding with the production of radicals such as superoxide and nitric oxide, which results in the formation of peroxynitrite, 46 may be one reason for the fact that seizure-induced protein nitration and glutamine synthetase inhibition are much more easily detectable in piriform and entorhinal cortices than in other regions. 40 The latter may also explain why certain other changes affecting neuro-transmitter metabolism seen in other rodent models of epilepsy seem to occur in a most pronounced manner in these cortices. 50 However, the question of why a neuronal induction of the heat shock protein 70 (HSP-70) family does not occur in PTZ models, whereas it is a normal finding in other rodent models of epilepsy, 51 still has to be explained, especially as HSP-70-overexpressing mice seem to be partly protected against PTZ-induced seizure activity. 52 As oxidative and nitrosative stress are not restricted to neurons that are functionally connected with glial cells and blood vessels, it may not be surprising that concomitant glial and endothelial changes do occur. The latter are seen by strong region-specific focal glial HSP-27 expression (see Figure 4) . HSP-27 is a well-established marker for oxidative stress. 21 As glial cells are well equipped to cope with pathological alterations and ongoing processes such as during scar formation, it is understandable that glial cells respond in a more delayed manner. 21 When focusing on currently used experimental models of epilepsy, glial responses have to be viewed as a secondary consequence of neuronal seizure activity 26 rather than an initial cause of seizures, as is sometimes suggested. 53, 54 Nevertheless, these secondary glial responses may subsequently contribute to a continuation or progression of epileptic seizures, for example during successful kindling.
Conclusion
In this article we have concentrated on two aspects of the PTZ model: neurotransmitter-receptor alterations and oxidative stress.
Consideration of these two topics alone is sufficient to reveal seizure-induced changes in the expression patterns of several genes, interactions among their gene products (proteins, e.g.
receptor subunits and enzymes) and interactions among the enzyme products (e.g. prostaglandins) or even their by-products and reaction products (e.g. superoxide, NO and peroxynitrite).
To gain insight into the complex in vivo interactions, animal experiments are essential. The complexity of these changes points to limitations of experimental gene therapy, 55 because enhancing the expression of genes that contribute to the production of increased amounts of inhibitory neurotransmitters, for example, may reduce the severity of the acute symptoms but still be far from curing the disease and its progression. n
